Compare GTLB & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTLB | LNTH |
|---|---|---|
| Founded | 2011 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.6B |
| IPO Year | 2021 | 2014 |
| Metric | GTLB | LNTH |
|---|---|---|
| Price | $46.91 | $99.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 27 | 6 |
| Target Price | $37.17 | ★ $87.00 |
| AVG Volume (30 Days) | ★ 5.3M | 901.1K |
| Earning Date | 06-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.91 |
| Revenue | ★ $955,224,000.00 | $343,374,000.00 |
| Revenue This Year | $18.72 | N/A |
| Revenue Next Year | $16.05 | $14.19 |
| P/E Ratio | ★ N/A | $34.27 |
| Revenue Growth | ★ 25.81 | 3.62 |
| 52 Week Low | $18.73 | $49.67 |
| 52 Week High | $55.55 | $111.86 |
| Indicator | GTLB | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 53.02 | 40.35 |
| Support Level | $46.01 | $98.81 |
| Resistance Level | $50.67 | $101.24 |
| Average True Range (ATR) | 1.74 | 0.45 |
| MACD | -0.51 | -0.03 |
| Stochastic Oscillator | 23.50 | 12.13 |
GitLab Inc operates on an all-remote model. GitLab is a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation, following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, & the Asia Pacific. It focused on accelerating innovation & broadening the distribution of its platform to companies across the world.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.